By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

VeroScience 

1334 Main Road

Tiverton  Rhode Island  02878  U.S.A.
Phone: 401-816-0525 Fax: 401-816-0524


SEARCH JOBS


Industry
Biotechnology

Segment
Start Up





Company News
VeroScience Is Pleased To Support Independent Research From The Laboratory Of Dr. Defronzo And Team At UT Health Science Center, San Antonio 6/13/2016 11:04:09 AM
VeroScience Continues To Explore Clinical Benefits Of Circadian Neuroendocrine Resetting Therapy With Six Papers Presented At 2016 American Diabetes Association Scientific Sessions June 10-14 6/13/2016 11:01:06 AM
Published Review Paper From VeroScience Delineates 50 Years Of Research Linking Circadian Rhythms With Metabolic Disease 3/16/2016 10:27:23 AM
VeroScience Release: Two Peer-Reviewed Studies Focusing On Unique Therapeutic Impact Of Veroscience's Cycloset Recently Published In Journal Of Diabetes Research 6/15/2015 7:59:49 AM
VeroScience Continues Clinical Evaluation of Bromocriptine-QR (Cycloset) And Neurophysiological Investigations Of Brain Dopamine Regulation Of Metabolism With Eight Papers Presented At The 2015 American Diabetes Association Conference 6/8/2015 6:46:34 AM
Santarus Inc. (SNTS) and VeroScience Announce CYCLOSET (bromocriptine mesylate) Data Presentations at the American Diabetes Association Meeting 6/21/2013 7:00:01 AM
Santarus Inc. (SNTS) and VeroScience Announce Publication of American Association of Clinical Endocrinologists Expert Panel Recommendations for CYCLOSET® (bromocriptine mesylate) for the Management of Type 2 Diabetes 3/6/2013 9:57:25 AM
Santarus Inc. (SNTS) and VeroScience Announce Publication of Positive Data From Pivotal CYCLOSET® (bromocriptine mesylate) Efficacy Study 1/23/2013 9:41:13 AM
Santarus Inc. (SNTS) Buys License To Make Diabetes Drug For $5 Mln From S2 Biosciences Inc. And VeroScience 9/9/2010 6:53:42 AM
VeroScience Announces FDA Approval of Cycloset for Treatment of Type 2 Diabetes 5/6/2009 8:33:07 AM
12
//-->